IMR Press / EJGO / Special Issues / 1638428461478

Hyperthermic Intraperitoneal Chemotherapy in Gynaecological Oncology 2022

Submission deadline: 31 May 2022
Special Issue Editors
Christos Iavazzo, MD
Gynaecological Oncology Department - Metaxa Cancer Hospital, Piraeus, Greece
Interests: robotics; laparoscopic surgery oncology
Special Issue Information

Dear Colleagues,
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) as a standard treatment procedure in the field of gynecologic oncology is controversial. Although widely discussed and studied as a subsidiary method of interval cytoreductive surgery, HIPEC is still being debated for the management of advanced and recurrent epithelial ovarian cancer (EOC). The results from many large trials support the safety and efficacy of HIPEC in well-selected EOC patients, where it has been shown to increase overall survival. Interestingly, recent findings support the effectiveness of HIPEC even when performed at the time of primary debulking surgery for stage III EOC patients in whom complete cytoreduction is anticipated. The results from large ongoing trials will soon be available. There are also promising results for HIPEC combined with adjuvant chemotherapy with platinum compounds in the management of advanced stage peritoneal-disseminated endometrial and cervical cancer. In patients with abdominally confined disease, HIPEC has been considered for peritoneal carcinomatosis of non-gynecological origin. Many authors have published evidence that supports explorative surgery followed by cytoreduction and HIPEC. Initially this was for cases of pseudomyxoma peritonei and malignant peritoneal mesothelioma, but was later followed by cases of gastric, colorectal and even breast cancer patients with pelvic peritoneal metastases.
Nevertheless, more prospective multi-center randomized studies are needed in order to draw conclusions about the safety of HIPEC and to determine which patients could benefit from its implementation. Further studies are also required to obtain robust data on the surgical procedures, the type and dose of chemotherapeutic regimens, and the temperature and duration of the hyperthermic arm needed to achieve optimal oncological outcomes. This information should help to support the recommendation of HIPEC in the gynecological cancer community.
The aim of this special issue is therefore to publish novel studies on the potential role of HIPEC in different gynecological cancers, through exploration of the indications, technique, and future challenges. We welcome authors to submit case reports, case series, retrospective studies, randomized trials and reviews in this field.

 

Prof. Dr. Christos Iavazzo

Guest Editor

Keywords
Gynecologic cancer
Hysteroscopy
Cancer prevention
Early diagnosis
Cancer screening
Pre-operative cancer workup
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top